
GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies
GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80 percent accuracy1, based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer (SITC) in San Diego, U.S., by GE HealthCare, Vanderbilt University Medical Center (VUMC) and the University Medicine Essen (UME), Germany. Originally developed based on a cohort of over 3,000 immunotherapy patients from VUMC and subsequently validated on a cohort of 4,000 patients from UME, the AI models predict efficacy outcomes and the likelihood of an individual patient developing an adverse reaction. This could enable precision care by unlocking the potential for clinicians to select the appropriate personalized treatment pathway sooner while potentially sparing unnecessary side effects and cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101659257/en/
T cells helping immune system to fight cancer cells in response to immunotherapies (Photo: Business Wire)
Immunotherapies use the immune system to recognize and attack cancer cells and can be more effective than traditional treatments, but response rates are often low and side effects can be severe.2 In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today3, selecting patients more likely to respond could also help drug developers to speed up and increase the likelihood of success of clinical trials. After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.
To develop the AI models, GE HealthCare and VUMC retrospectively analyzed and correlated the immunotherapy treatment response of thousands of VUMC cancer patients, with their deidentified demographic, genomic, tumor, cellular, proteomic, and imaging data. The models presented at SITC use only routinely acquired data from the patient's electronic health record (EHR) as inputs, enabling versatility and scalability in their potential application.
“Immunotherapy can offer significant benefits for patients but given the current unpredictability of some reactions to treatment, it can also be associated with increased morbidity and cost. These results pave the way for the ability to better select which patients should benefit and which would be better suited to an alternative form of treatment,” said Travis Osterman, DO, MS, Associate Vice President for Research Informatics and Associate Chief Medical Information Officer for Vanderbilt University Medical Center, and Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center.
"In our joint work, we have shown that the AI models are effective across both sides of the Atlantic, paving the way for real world applications that could offer significant benefits for cancer patients treated with immunotherapies." said Jens Kleesiek, MD, PhD, Head of the Medical Machine Learning Department at the Institute for AI in Medicine and Associate Director of the West German Cancer Center of the University Medicine Essen.
“These results are a promising development in the journey towards precision care, selecting treatment pathways based on the individual patient’s likely response. We are keen to partner with pharmaceutical companies, researchers, and clinicians to optimize and apply our AI models in therapy development and in clinical practice in a longer term,” said Julia Casey, General Manager Molecular Imaging at GE HealthCare’s Pharmaceutical Diagnostics segment.
The AI models are an integral part of GE HealthCare’s immuno-oncology development portfolio which includes the development of novel PET tracers. The company recently announced the first patient scanned in a Phase I clinical trial of a first-of-its kind fluorine-18 PET radiopharmaceutical specific for CD8. Almost all immunotherapies work by activating CD8+ T cells - a subpopulation of white blood cells which fight cancer - both within and outside a tumor.
GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology, and oncology, with an innovative pipeline, all aimed at enabling better-informed diagnosis and monitoring for improved therapy decision-making and clinical outcomes.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is the largest comprehensive research, teaching and patient care health system in the Mid-South region of the U.S., with the highest ranked adult and children’s hospitals in the Southeast by U.S. News & World Report. Based in Nashville, Tennessee, VUMC sees more than 3.2 million patient visits per year in over 180 ambulatory locations, performs 91,000 surgical operations and discharges 79,000 inpatients from its main-campus adult, children’s, psychiatric and rehabilitation hospitals and three regional community hospitals. The Medical Center is the largest non-governmental employer of Middle Tennesseans, with nearly 40,000 staff, including more than 3,000 physicians, advanced practice nurses and scientists appointed to the Vanderbilt University faculty. For more information and the latest news follow VUMC on Facebook, LinkedIn, Twitter and in the VUMC Reporter.
About The University Medicine Essen (UME)
Including its four subsidiary hospitals, University Medicine Essen comprises a total of 32 clinics and 24 institutes. Around 10,000 experts provide their know-how for more than 70,000 inpatients and 300,000 outpatients per year. Several hundred physicians and scientists work together at the West German Cancer Center Essen, the comprehensive cancer center of the University Hospital Essen, to offer cancer patients innovative interdisciplinary treatment programs and individualized therapies. With standout categories in electronic functionalities and artificial intelligence, UME is ranked in the top 20 of Newsweek World's Best Smart Hospitals 2023.
1 Poster “Evaluation of Machine Learning Models to Predict Efficacy and Toxicity of Immune Checkpoint Inhibitors Using an External Real-World Pan-Cancer Cohort” to be presented at SITC 38th Annual meeting
2https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief#:~:text=It%20doesn't%20work%20for,are%20about%2015%20to%2020%25. Accessed on October 31, 2023.
3 Shankar L. et al. Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. Lancet Oncology 2023; 24(3): e133-e143. doi: 10.1016/S1470-2045(22)00742-2
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101659257/en/
Contact information
GE HealthCare Media Contact:
Mathilde Bouscaillou
+33 647 008 271
Mathilde.bouscaillou@ge.com
Vanderbilt University Medical Center Media Contact:
John Howser
615-322-4747
John.howser@vumc.org
University Medicine Essen Media Contact:
Achim Struchholz
Achim.Struchholz@uk-essen.de
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New VCMI Guidance Opens Door for Corporate Carbon Credit Claims28.11.2023 11:36:00 CET | Press release
The Voluntary Carbon Markets Integrity Initiative (VCMI) has today released additional guidance for its Claims Code of Practice (Claims Code), enabling companies to make claims about their use of high-quality carbon credits. This guidance includes a Monitoring, Reporting and Assurance (MRA) Framework, a brand and associated mark for making ‘Carbon Integrity' Claims, and a beta version of an additional claim. Using the MRA framework and the ‘Carbon Integrity’ Claims branding, companies can now make Silver, Gold or Platinum Claims as outlined in the original Claims Code of Practice released in June. This means these companies can now make claims using high-quality carbon credits, directing finance to initiatives that mitigate climate change, and demonstrating that they are going above and beyond science-aligned emissions cuts. VCMI has also launched the beta version of a new claim – called the ‘Scope 3 Flexibility’ Claim - as a practical step to accelerate corporate climate action. Once
inDrive welcomes Stephen Kruger as Chief Technology and Product Officer28.11.2023 10:00:00 CET | Press release
inDrive, a global mobility and urban services platform, announces the appointment of Stephen Kruger as its Chief Technology and Product Officer. Stephen will be responsible for implementing inDrive’s technology and product development strategies as the company continues to expand into new geographies and business verticals. inDrive has built out its platform with geography-specific freight and courier offerings, as well as handyman services, in addition to its core ride-hailing business. The combined technology and product team is tasked with continuing to scale inDrive’s platform, implementing new product features to support growth and further diversification of the business. Welcoming Stephen to the team, inDrive founder and CEO Arsen Tomsky said: "Stephen's remarkable background in technology leadership aligns seamlessly with our vision for inDrive's future. His proven ability to drive organizational change and innovation will undoubtedly strengthen our position in the industry whil
Reply Awarded With Two 2023 AWS Partner Awards: System Integrator Partner of the Year EMEA and Energy and Utilities Partner of the Year Global28.11.2023 09:30:00 CET | Press release
Reply, a global systems integrator and consulting firm and AWS Premier Consulting partner, is excited to announce it is a recipient of two 2023 Geo and Global AWS Partner Awards, which recognize leaders around the globe playing a key role helping customers drive innovation and build solutions on Amazon Web Services (AWS). The Geo and Global AWS Partner Awards celebrate a wide range of AWS Partners, whose business models have embraced specialization, innovation, and cooperation over the past year. Geo and Global AWS Partner Awards recognize partners whose business models continue to evolve and thrive on AWS as they work with customers. A panel of AWS experts selected the winners based on strict criteria. Reply is excited to announce it has received: - Global Industry Partner of the Year – Energy and Utilities, which recognizes top AWS Partners with the AWS Energy Competency who help customers build and implement advanced solutions powered by AWS across the industry value chain. Leveragi
Regula Shares Identity Verification Trends to Shape 2024 and Beyond28.11.2023 09:00:00 CET | Press release
Staying ahead in ID verification ensures a secure and flourishing future for organizations. This is why Regula experts are releasing their forecast for the trends for 2024 and beyond. Based on an analysis of recent developments in the IDV area, the experts highlighted nine trends, with those revolving around identity fraud being the most critical. Liveness-centric approach and authenticity cross-checks as the only options to prevent sophisticated identity fraud Addressing identity fraud is crucial, with 43% prioritizing it, according to Regula’s survey. To succeed in combating document fraud and counterfeiting, IDV vendors must go beyond basic checks and enable comprehensive cross-referencing of all the data. This will be one of the major trends when developing IDV solutions in the coming years. Cross-referencing all the data in the document, including biometric checks, makes it possible to identify inconsistencies that may signal fraud. For example, a fraudster might attempt to replac
Bibby Financial Services Chooses FGI T.R.U.S.T.™ for Strategic Partnership28.11.2023 09:00:00 CET | Press release
FGI Worldwide LLC (“FGI”), a global leader in commercial finance, today announced that the UK’s largest independent invoice finance provider, Bibby Financial Services (“BFS”), has chosen FGI T.R.U.S.T.™ as its software platform for bad debt protection management and administration. FGI T.R.U.S.T.™ is a cloud-based platform that combines technology with functionality to enable corporations, brokers, and lenders to maximize and automate the administration of credit insurance policies. BFS chose T.R.U.S.T.™ over other platforms due to its robust features and the team’s flexible, solutions-oriented approach to the partnership. The collaborative, multi-month implementation process was completed ahead of schedule. “BFS is a world-renowned leader in the financial services industry, and FGI is proud to support its continued advancement with our T.R.U.S.T.™ technology,” commented Sami Altaher, President of FGI. “This partnership is the latest step in FGI’s global expansion as lenders recognize